Results 1 to 10 of about 9,928,312 (178)

Metastatic Extrapulmonary Small Cell Carcinoma Presenting as Obstructive Jaundice [PDF]

Case Reports in Oncology, 2022
Extrapulmonary small cell carcinoma (EPSCC) is a rare cancer with a poor prognosis. It can arise from almost any site and is usually associated with extensive metastasis at the time of diagnosis.
Ejaz Shah, Calvin Abro
doaj   +6 more sources

Extrapulmonary Small Cell Carcinoma of the Stomach: A Lethal Entity [PDF]

Case Reports in Gastroenterology, 2010
Extrapulmonary small cell carcinoma of the stomach is a rare and aggressive malignancy with a poor prognosis that was first described in 1976 by Matsusaka et al.
Duane Moise, Jaspreet Singh, Keith Dahl, Sadat Rashid, Apsara Prasad, Ghulam Siddiqui, Krishnaiyer Subramani, Paul Mustacchia, Kaleem Rizvon   +8 more
doaj   +6 more sources

Primary small cell carcinoma of the adrenal gland: Case presentation of a rare extrapulmonary small cell carcinoma [PDF]

Urology Case Reports, 2020
Small cell carcinoma (SCC) is an aggressive histologic subtype of neuroendocrine tumor and is most commonly of bronchogenic origin. However, it can present in an extrapulmonary fashion.
Jennifer Y. Lee, David Strauss, Kelly Bailey, Marc Smaldone   +3 more
doaj   +6 more sources

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab [PDF]

Radiology Case Reports
Two basic criteria must be met for the diagnosis of extrapulmonary small cell carcinoma (EPSCC): the tumor must present histological characteristics of small cell carcinoma and a primary small cell lung carcinoma must be ruled out. We present the case of
Alfredo S. Golemba, MD, Astor A. Aguirre Santamaría, MD, Raúl E. García Tolosa, MD   +2 more
doaj   +5 more sources

An online tool for survival prediction of extrapulmonary small cell carcinoma with random forest [PDF]

Frontiers in Oncology, 2023
PurposeExtrapulmonary small cell carcinoma (EPSCC) is rare, and its knowledge is mainly extrapolated from small cell lung carcinoma. Reliable survival prediction tools are lacking.MethodsA total of 3,921 cases of EPSCC were collected from the ...
Xin Zhang, Xin Zhang
doaj   +4 more sources

Extrapulmonary Small Cell Carcinoma of the Anal Canal: A Case Report and Review of the Literature [PDF]

Case Reports in Medicine, 2012
Purpose. Extrapulmonary small cell carcinoma affecting the anal canal is a rare and poorly understood entity which can, in its early stages, masquerade as benign anorectal disease such as hemorrhoids. Methods.
Joshua M. Eberhardt, Karen Brown, Shelly Lo, Suneel Nagda, Sherri Yong   +4 more
doaj   +3 more sources

Merkel cell polyomavirus and extrapulmonary small cell carcinoma. [PDF]

Oncol Lett, 2013
The Merkel cell polyomavirus (MCV) is involved in the development of up to 100% of Merkel cell cancer (MCC) cases. Early studies have reported that the virus was infrequently detected in other small cell or neuroendocrine lung carcinomas, which share histological features with MCC.
Hourdequin KC, Lefferts JA, Brennick JB, Ernstoff MS, Tsongalis GJ, Pipas JM.   +5 more
europepmc   +4 more sources

Adrenocorticotropic Hormone-producing Extrapulmonary Small Cell Carcinoma of the Breast. [PDF]

Cureus, 2019
Extrapulmonary small cell carcinoma (EPSCC) of the breast is a very rare tumor. Adrenocorticotropic hormone (ACTH) production from these tumors is extremely rare and seldom reported resulting in significant diagnostic and therapeutic challenges and delays. We present a case of a 38-year-old female who presented with a breast lump and was diagnosed with
Abu Khalaf S, Mansour AM, Chela H.
europepmc   +4 more sources

KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

Balkan Medical Journal, 2016
Background: Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Extrapulmonary small cell carcinomas (EPSCC) are very rare.
Hilmi Kodaz, Ebru Taştekin, Bülent Erdoğan, İlhan Hacıbekiroğlu, Hilmi Tozkır, Hakan Gürkan, Esma Türkmen, Bora Demirkan, Sernaz Uzunoğlu, İrfan Çiçin   +9 more
doaj   +5 more sources

Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma [PDF]

JTO Clinical and Research Reports
Introduction: SCLC remains the most aggressive lung cancer with a poor prognosis. Tarlatamab, a bispecific T-cell engager, is approved for use in extensive-stage SCLC after progression on a platinum-based chemotherapy on the basis of the DeLLphi-301 ...
Sanjana Mullangi, MD, Manidhar Reddy Lekkala, MD, Sarah Blocker, PharmD, Diana Kim, PharmD, Jun Zhang, MD, Chao Huang, MD, Prakash Neupane, MD, Haoran Li, MD, Timothy Schieber, PharmD   +8 more
doaj   +2 more sources